Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

KOREAN POST-MARKETING SURVEILLANCE VYNDAMAX (REGISTERED) CAPSULES FOR THE TREATMENT OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)

NCT04801329 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04801329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04801329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
KOREAN POST-MARKETING SURVEILLANCE VYNDAMAX (REGISTERED) CAPSULES FOR THE TREATMENT OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
June 29, 2021
Completion date
April 21, 2026
Enrollment
110 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

attr-cm (transthyretin amyloid cardiomyopathy)